Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor in Combination With Gemcitabine and Cisplatin in Advanced Cancer (Study P01499)(TERMINATED)

Inclusion Criteria:

• Advanced cancer for which there is no treatment available which would have a reasonable chance of disease palliation or cure
• Age greater than or equal to 18.
• SWOG performance Status less than or equal to 2.
• Meets protocol requirements for specified laboratory values.
• Written informed consent and cooperation of patient.

Exclusion Criteria:

• Prior treatment with an FPTI
• Knowledge of intracranial metastases or carcinomatous meningitis.
• Poor medical risks because of nonmalignant systemic disease or uncontrolled active infection.
• Medical conditions that would interfere with taking oral medications.
• Significant uncontrolled diarrhea.
• Chemotherapy, radiotherapy or major surgery within 4 weeks; full recovery from prior treatment.
• Concomitant use of CYP3A inhibitors/inducers per protocol.
• Known HIV positivity or AIDS-related illness.
• Pregnant or nursing women.
• Men or women of childbearing potential who are not using an effective method of contraception.
• Concurrent chemotherapy, hormonal therapy, radiotherapy or immunotherapy.
• QTc prolongation (>440 msecs) at baseline.
• Patients with previous high-dose therapy requiring stem cell rescue or bone marrow transplant, or irradiation to >30% of bone marrow-containing areas.
• Patients that have received Mitomycin-C or nitrosoureas.